Stephens Boosts Illumina (NASDAQ:ILMN) Price Target to $184.00

Illumina (NASDAQ:ILMN) had its price target upped by equities research analysts at Stephens from $170.00 to $184.00 in a report issued on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the life sciences company’s stock. Stephens’ target price suggests a potential upside of 25.88% from the company’s current price.

Several other equities research analysts have also issued reports on the stock. TD Cowen raised their target price on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a research note on Thursday, October 17th. StockNews.com started coverage on Illumina in a research note on Thursday, August 29th. They set a “buy” rating on the stock. Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price target for the company in a research note on Thursday, October 17th. Finally, Canaccord Genuity Group increased their target price on Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $164.00.

Illumina Stock Down 1.0 %

Shares of NASDAQ:ILMN opened at $146.17 on Tuesday. The company has a 50-day moving average price of $138.84 and a 200 day moving average price of $123.95. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina has a 12 month low of $92.69 and a 12 month high of $156.66. The company has a market cap of $23.18 billion, a price-to-earnings ratio of -14.68 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.33 EPS. As a group, equities research analysts predict that Illumina will post 4.11 earnings per share for the current year.

Hedge Funds Weigh In On Illumina

A number of large investors have recently added to or reduced their stakes in ILMN. Jupiter Asset Management Ltd. acquired a new position in shares of Illumina during the first quarter valued at about $4,527,000. US Bancorp DE increased its stake in Illumina by 33.9% during the 1st quarter. US Bancorp DE now owns 31,600 shares of the life sciences company’s stock valued at $4,339,000 after purchasing an additional 8,001 shares in the last quarter. Cetera Advisors LLC purchased a new position in shares of Illumina in the first quarter worth $610,000. Weybosset Research & Management LLC grew its holdings in shares of Illumina by 92.0% during the third quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock valued at $2,354,000 after buying an additional 8,650 shares during the last quarter. Finally, Sei Investments Co. increased its position in shares of Illumina by 309.3% in the 1st quarter. Sei Investments Co. now owns 71,143 shares of the life sciences company’s stock valued at $9,769,000 after acquiring an additional 53,761 shares during the period. 89.42% of the stock is currently owned by institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.